Citigroup Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $14.00

Larimar Therapeutics (NASDAQ:LRMR) had its price target increased by stock analysts at Citigroup from $12.00 to $14.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s target price indicates a potential upside of 126.57% from the company’s current price.

Other equities analysts have also issued research reports about the stock. Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Larimar Therapeutics in a report on Wednesday. Leerink Partners upgraded Larimar Therapeutics to a “strong-buy” rating in a research note on Monday, January 5th. Lifesci Capital raised Larimar Therapeutics to a “strong-buy” rating in a research report on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Larimar Therapeutics presently has an average rating of “Buy” and an average target price of $16.14.

Larimar Therapeutics Trading Up 67.5%

Shares of Larimar Therapeutics stock traded up $2.49 during trading hours on Wednesday, reaching $6.18. The stock had a trading volume of 70,082,940 shares, compared to its average volume of 4,769,893. The firm has a market capitalization of $511.49 million, a price-to-earnings ratio of -3.24 and a beta of 1.01. Larimar Therapeutics has a 1 year low of $1.61 and a 1 year high of $6.42. The firm has a 50 day simple moving average of $3.44 and a two-hundred day simple moving average of $3.76.

Institutional Investors Weigh In On Larimar Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its position in Larimar Therapeutics by 75.8% during the third quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock valued at $33,000 after purchasing an additional 4,376 shares during the last quarter. Savant Capital LLC acquired a new stake in Larimar Therapeutics during the 2nd quarter worth approximately $39,000. B.O.S.S. Retirement Advisors LLC bought a new stake in shares of Larimar Therapeutics in the third quarter worth $41,000. Coldstream Capital Management Inc. acquired a new stake in Larimar Therapeutics during the 3rd quarter valued at approximately $57,000. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Larimar Therapeutics by 33.9% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 18,248 shares of the company’s stock worth $59,000 after buying an additional 4,619 shares during the period. Institutional investors own 91.92% of the company’s stock.

Key Larimar Therapeutics News

Here are the key news stories impacting Larimar Therapeutics this week:

• Positive Sentiment: FDA granted Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia; Larimar reiterated plans to submit a BLA in June 2026 with topline open‑label data expected Q2 2026 and a potential U.S. launch in H1 2027 — this materially raises the drug’s regulatory and commercial prospects. Press release: Larimar Announces FDA Breakthrough Therapy Designation
• Positive Sentiment: Analyst support picked up: Wedbush reaffirmed an “outperform” rating and placed an $11 price target (roughly +85% from the pre-news level cited), which can validate upside expectations and attract momentum buyers. Benzinga
• Positive Sentiment: Lifesci Capital upgraded LRMR to a “strong-buy”, adding further buy-side signals that can support continued inflows from retail and institutional investors. Zacks.com
• Positive Sentiment: Unusual options activity: traders bought ~3,744 call contracts (≈+456% vs. typical daily call volume), indicating speculative bullish positioning that often accompanies rapid share-price rallies and can amplify short‑term volatility and buying pressure.
• Neutral Sentiment: Broad media coverage and explanatory articles explaining the FDA designation and share surge have increased visibility and may attract additional speculative interest. Investing.com: Larimar stock surges on FDA breakthrough status
• Neutral Sentiment: Multiple outlets summarized the move and drivers (MSN, AAII), which helps explain the rally to a wider audience but does not itself change fundamentals. MSN: Larimar surges on FDA breakthrough status

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.